DNA repair pathways are evolutionarily conserved molecular mechanisms that maintain the integrity of genomic DNA. In cancer therapies, the integrity and activity of DNA repair pathways predict therapy resistance and disease outcome. Members of the poly (ADP-ribose) polymerase (PARP) family initiate and organize the biologic process of DNA repair, which counteracts many types of chemotherapies. Since the first development in approximately 3 decades ago, PARP inhibitors have greatly changed the concept of cancer therapy, leading to encouraging improvements in tumor suppression and disease outcomes. Here we summaries both pre-clinical and clinical findings of PARP inhibitors applications, particularly for combination therapies.

DNA修复途径是进化保守的分子机制，可维持基因组DNA的完整性。在癌症治疗中，DNA修复途径的完整性和活性可预测治疗耐药性和疾病结局。聚（ADP-核糖）聚合酶（PARP）家族的成员启动并组织了DNA修复的生物学过程，这抵消了许多类型的化学疗法。自大约三十年前的第一个发展以来，PARP抑制剂极大地改变了癌症治疗的概念，从而导致令人鼓舞的肿瘤抑制和疾病结果改善。在这里，我们总结了PARP抑制剂的临床前和临床发现，尤其是对于联合疗法。